ERBB2 and neoplasm: One of the most common inhibitors of HER2 is trastuzumab, a monoclonal antibody that binds to the extracellular domain of HER2 and inhibits several major downstream signaling pathways that regulate tumor growth, such as the RAS/RAF/MEK/MAPK and the PI3K/AKT pathways [20,21].